# Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

> **NCT00107016** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 267 (actual)

## Conditions studied

- Breast Neoplasm

## Interventions

- **DRUG:** RAD001, Letrozole 2.5mg
- **DRUG:** Letrozole 2.5mg

## Key facts

- **NCT ID:** NCT00107016
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2013-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00107016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00107016, "Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00107016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*